Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 5, 2006, Pages 599-610

  Posey, David J ^a,b   Wiegand, Ryan E ^a   Wilkerson, Jennifer ^a   Maynard, Melissa ^a   Stigler, Kimberly A ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE;

ABDOMINAL DISCOMFORT; ABERRANT BEHAVIOR CHECKLIST; ADOLESCENT; ANXIETY; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONNERS CONTINUOUS PERFORMANCE TEST; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE MOVEMENT DISORDER; FEMALE; HUMAN; INSOMNIA; INTELLIGENCE QUOTIENT; IRRITABILITY; MALE; MOOD DISORDER; MYDRIASIS; NAUSEA; NOCTURNAL ENURESIS; OPEN STUDY; PERFORMANCE; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PROSPECTIVE STUDY; PSYCHOSOCIAL WITHDRAWAL; QUESTIONNAIRE; RATING SCALE; SEDATION; SIDE EFFECT; SPEECH DISORDER; STANDARDIZATION; STATISTICAL SIGNIFICANCE; STEREOTYPY; SWANSON NOLAN AND PELHAM QUESTIONNAIRE; SYMPTOMATOLOGY; THIRST; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUTISTIC DISORDER; BODY WEIGHT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTELLIGENCE; IRRITABLE MOOD; MALE; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PROPYLAMINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33750944897     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.599     Document Type: Article

References (37)

1. Aman MG, Singh NN, Stewart AW, Field CJ: The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Deficiency 89:485-491, 1985.
2. th edition. Washington, DC, American Psychiatric Association, 1994.
3. Box GEP, Cox DR: An analysis of transformations. J Royal Stat Soc 6-26:211-252, 1964.
4. Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C: Response to triiodothyronine and dextroamphetamine: A study of preschool schizophrenic children. J Autism Child Schizophr 2:343-358, 1972.
5. Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser N: Levodopa and levoamphetamine: A crossover study in young schizophrenic children. Curr Ther Res Clin Exp 19:70-86, 1976.
6. Chakrabarti S, Fombonne E: Pervasive developmental disorders in preschool children. JAMA 285:3093-3099, 2001.
7. Conners CK: Conners' Continuous Performance Test-II. North Tonawanda (New York), Multi-Health Systems, Inc., 2000.
8. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W: Validation of a brief quantitative measure of autistic traits: Comparison of the Social Responsiveness Scale with the Autism Diagnostic Interview-Revised. J Autism Dev Disord 33:427-433, 2003.
9. Frankhauser MP, Karumanchi VC, German ML, Yates A: A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53:77-82, 1992.
10. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447, 1993.
11. st Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington (DC), October 19-24, 2004.
12. Guy W: ECDEU assessment manual for psychopharmacology (NIMH Publication No. 76-338). Washington, DC, U.S. DHEW, NIMH, 1976.
13. Handen BL, Johnson CR, Lubetsky M: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245-255, 2000.
14. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R: A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582-589, 2005.
15. Hsu JC: The factor analytic approach to simultaneous inference in the general linear model. J Comp Graph Stats 1:151-168, 1992.
16. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322-327, 1992.
17. Jou RJ, Handen BL, Hardan AY: Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15:325-330, 2005.
18. Kanner L: Autistic disturbance of affective contact. Nervous Child 2:217-250, 1943.
19. Lecavalier L: Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. J. Autism Dev Disord Aug 2, 2006 [Epub] ahead of print].
20. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disorder 24:659-686, 1994.
21. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M: The Autism Diagnostic Observation Schedule-Generic: A standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30:205-223, 2000.
22. McDougle CJ, Posey D: Autistic and other pervasive developmental disorders. In: Pediatric Psychopharmacology: Principles and Practice. Edited by Martin A, Scahill L, Charney D, Leckman JF. New York, Oxford University Press, 2003, pp 563-579.
23. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996.
24. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641, 1998.
25. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:e83, 2001.
26. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120, 2003.
27. Posey DJ, Putney JI, Sasher TM, Kem DL, McDougle CJ: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233-24, 2004a.
28. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ: A pilot study of D-cycloserine in autistic disorder. Am J Psychiatry 161:2115-2117, 2004b.
29. Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, Greenhill L: Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25:283-294, 1995.
30. Roid GH, Miller LJ: Leiter-R: Leiter International Performance Scale-Revised. Wood Dale (Illinois), Steeling Co., 1997.
31. RUPP Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
32. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274, 2005.
33. SAS Institute, Inc.: SAS Version 9.1. Cary (North Carolina), SAS Institute, 2004.
34. Sparrow SS, Balla DA, Cicchetti DV: Vineland Adaptive Behavior Scales. Circle Pines (Minnesota), American Guidance Service, Inc., 1984.
35. Spencer T, Biederman J, Heiligenstein J, Wilens T, Paries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S: An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251-265, 2001.
36. Swanson JM: School-Based Assessments and Interventions for ADD Students. Irvine (California), KC Publishing, 1992.
37. rd ed. San Antonio (Texas), Psychological Corporation, 1999.